NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or the “Company”) (NASDAQ: BPMC). Such investors are advised to contact Robert S. Willoughby at


[email protected]


or 888-476-6529, ext. 7980.

The investigation concerns whether Blueprint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 9, 2022, Blueprint issued a press release disclosing that the Company “plans to update the primary endpoint of the registrational PIONEER trial of AYVAKIT in patients with non-advanced SM, based on a written recommendation from the U.S. Food and Drug Administration (FDA) on statistical considerations ahead of the planned database lock.”

On this news, Blueprint’s stock price fell $5.73 per share, or 8.88%, to close at $58.77 per share on June 9, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See


www.pomlaw.com

CONTACT:


Robert S. Willoughby

Pomerantz LLP


[email protected]




888-476-6529 ext. 7980